10 PRIMECAP Management Neurocrine Biosciences Trades
PRIMECAP Management's position in Neurocrine Biosciences is currently worth $44.3 Million. That's 0.04% of their equity portfolio (187th largest holding). The first Neurocrine Biosciences trade was made in Q4 2022. Since then PRIMECAP Management bought shares five more times and sold shares on four occasions. The stake costed the investor $40.1 Million, netting the investor a gain of 10% so far.
Avg closing price
Price range
Sold 2.9% shares (-11.3 Thousand shares)
Q1 2025
Avg closing price
$126.95
Price range
$107.22
-
$153.29
Sold 2.5% shares (-10.3 Thousand shares)
Q4 2024
Avg closing price
$124.14
Price range
$111.62
-
$139.44
Sold 1.3% shares (-5.29 Thousand shares)
Q3 2024
Avg closing price
$136.96
Price range
$114.55
-
$153.15
Increased shares by 2.5% (+9.91 Thousand shares)
Q2 2024
Avg closing price
$137.14
Price range
$130.86
-
$143.19
Increased shares by 0.3% (+1.06 Thousand shares)
Q1 2024
Avg closing price
$136.57
Price range
$130.40
-
$143.74
Increased shares by 1.7% (+6.74 Thousand shares)
Q4 2023
Avg closing price
$115.11
Price range
$106.07
-
$132.76
Sold 0.5% shares (-1.78 Thousand shares)
Q3 2023
Avg closing price
$105.30
Price range
$94.02
-
$117.10
Increased shares by 5.8% (+21.6 Thousand shares)
Q2 2023
Avg closing price
$97.71
Price range
$89.53
-
$104.87
Increased shares by 7189.0% (+367 Thousand shares)
Q1 2023
Avg closing price
$104.06
Price range
$94.11
-
$123.02
New holding (+5.1 Thousand shares)
Q4 2022
Avg closing price
$117.13
Price range
$106.72
-
$127.06
News about Neurocrine Biosciences, Inc. and PRIMECAP Management
E Fund Management Co. Ltd. Grows Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
E Fund Management Co. Ltd. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 18.7% in the second quarter, accordi...
Top 5 1st Quarter Trades of Logos Global Management LP
Related Stocks: BCYC , NBIX , ALGS , RPTX , MRTX ,